Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas

S. M. Rodriguez-Pinilla; M. E C Sanchez; J. Rodriguez; J. F. Garcia; B. Sanchez-Espiridion; L. F. Lamana; G. Sosa; J. C. Rivero; J. Menarguez; I. B. Gomez; F. I. Camacho; P. R. Guillen; C. P S Orduna; G. Rodriguez; C. Barrionuevo; R. Franco; M. Mollejo; J. F. Marco; R. D. De Otazu; M. A. Piris

doi:10.1038/bcj.2013.10

Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas

S. M. Rodriguez-Pinilla, M. E C Sanchez, J. Rodriguez, J. F. Garcia, B. Sanchez-Espiridion, L. F. Lamana, G. Sosa, J. C. Rivero, J. Menarguez, I. B. Gomez, F. I. Camacho, P. R. Guillen, C. P S Orduna, G. Rodriguez, C. Barrionuevo, R. Franco, M. Mollejo, J. F. Marco, R. D. De Otazu, M. A. Piris

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article › peer-review

Abstract

Nodal peripheral T-cell lymphoma (nodal PTCL) has an unfavorable prognosis, and specific pathogenic alterations have not been fully identified. The biological and clinical relevance of the expression of CD30/T-cell receptor (TCR) genes is a topic under active investigation. One-hundred and ninety-three consecutive nodal PTCLs (89 angioimmunoblastic T-cell lymphomas (AITL) and 104 PTCL-unspecified (PTCL-not otherwise specified (NOS)) cases) were analyzed for the immunohistochemical expression of 19 molecules, involving TCR/CD30 pathways and the associations with standard prognostic indices. Mutually exclusive expression was found between CD3 and TCR-beta F1 with CD30 expression. Taking all PTCL cases together, logistic regression identified a biological score (BS) including TCR molecules (TCR-beta F1 and EZRIN) that separates two subgroups of patients with a median survival of 34.57 and 5.20 months (P

Original language	English
Article number	e111
Journal	Blood Cancer Journal
Volume	3
Issue number	4
DOIs	https://doi.org/10.1038/bcj.2013.10
Publication status	Published - Apr 2013

Keywords

BLIMP1
EZRIN
JUNB
T-cell lymphoma
TCR-beta F1

ASJC Scopus subject areas

Oncology
Hematology

Access to Document

10.1038/bcj.2013.10

Cite this

Rodriguez-Pinilla, S. M., Sanchez, M. E. C., Rodriguez, J., Garcia, J. F., Sanchez-Espiridion, B., Lamana, L. F., Sosa, G., Rivero, J. C., Menarguez, J., Gomez, I. B., Camacho, F. I., Guillen, P. R., Orduna, C. P. S., Rodriguez, G., Barrionuevo, C., Franco, R., Mollejo, M., Marco, J. F., De Otazu, R. D., & Piris, M. A. (2013). Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas. Blood Cancer Journal, 3(4), [e111]. https://doi.org/10.1038/bcj.2013.10

Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas. / Rodriguez-Pinilla, S. M.; Sanchez, M. E C; Rodriguez, J.; Garcia, J. F.; Sanchez-Espiridion, B.; Lamana, L. F.; Sosa, G.; Rivero, J. C.; Menarguez, J.; Gomez, I. B.; Camacho, F. I.; Guillen, P. R.; Orduna, C. P S; Rodriguez, G.; Barrionuevo, C.; Franco, R.; Mollejo, M.; Marco, J. F.; De Otazu, R. D.; Piris, M. A.

In: Blood Cancer Journal, Vol. 3, No. 4, e111, 04.2013.

Research output: Contribution to journal › Article › peer-review

Rodriguez-Pinilla, SM, Sanchez, MEC, Rodriguez, J, Garcia, JF, Sanchez-Espiridion, B, Lamana, LF, Sosa, G, Rivero, JC, Menarguez, J, Gomez, IB, Camacho, FI, Guillen, PR, Orduna, CPS, Rodriguez, G, Barrionuevo, C, Franco, R, Mollejo, M, Marco, JF, De Otazu, RD & Piris, MA 2013, 'Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas', Blood Cancer Journal, vol. 3, no. 4, e111. https://doi.org/10.1038/bcj.2013.10

Rodriguez-Pinilla, S. M. ; Sanchez, M. E C ; Rodriguez, J. ; Garcia, J. F. ; Sanchez-Espiridion, B. ; Lamana, L. F. ; Sosa, G. ; Rivero, J. C. ; Menarguez, J. ; Gomez, I. B. ; Camacho, F. I. ; Guillen, P. R. ; Orduna, C. P S ; Rodriguez, G. ; Barrionuevo, C. ; Franco, R. ; Mollejo, M. ; Marco, J. F. ; De Otazu, R. D. ; Piris, M. A. / Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas. In: Blood Cancer Journal. 2013 ; Vol. 3, No. 4.

@article{731767766bdc451191f71cfee4f700aa,

title = "Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas",

abstract = "Nodal peripheral T-cell lymphoma (nodal PTCL) has an unfavorable prognosis, and specific pathogenic alterations have not been fully identified. The biological and clinical relevance of the expression of CD30/T-cell receptor (TCR) genes is a topic under active investigation. One-hundred and ninety-three consecutive nodal PTCLs (89 angioimmunoblastic T-cell lymphomas (AITL) and 104 PTCL-unspecified (PTCL-not otherwise specified (NOS)) cases) were analyzed for the immunohistochemical expression of 19 molecules, involving TCR/CD30 pathways and the associations with standard prognostic indices. Mutually exclusive expression was found between CD3 and TCR-beta F1 with CD30 expression. Taking all PTCL cases together, logistic regression identified a biological score (BS) including TCR molecules (TCR-beta F1 and EZRIN) that separates two subgroups of patients with a median survival of 34.57 and 5.20 months (P",

keywords = "BLIMP1, EZRIN, JUNB, T-cell lymphoma, TCR-beta F1",

author = "Rodriguez-Pinilla, {S. M.} and Sanchez, {M. E C} and J. Rodriguez and Garcia, {J. F.} and B. Sanchez-Espiridion and Lamana, {L. F.} and G. Sosa and Rivero, {J. C.} and J. Menarguez and Gomez, {I. B.} and Camacho, {F. I.} and Guillen, {P. R.} and Orduna, {C. P S} and G. Rodriguez and C. Barrionuevo and R. Franco and M. Mollejo and Marco, {J. F.} and {De Otazu}, {R. D.} and Piris, {M. A.}",

year = "2013",

month = apr,

doi = "10.1038/bcj.2013.10",

language = "English",

volume = "3",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas

AU - Rodriguez-Pinilla, S. M.

AU - Sanchez, M. E C

AU - Rodriguez, J.

AU - Garcia, J. F.

AU - Sanchez-Espiridion, B.

AU - Lamana, L. F.

AU - Sosa, G.

AU - Rivero, J. C.

AU - Menarguez, J.

AU - Gomez, I. B.

AU - Camacho, F. I.

AU - Guillen, P. R.

AU - Orduna, C. P S

AU - Rodriguez, G.

AU - Barrionuevo, C.

AU - Franco, R.

AU - Mollejo, M.

AU - Marco, J. F.

AU - De Otazu, R. D.

AU - Piris, M. A.

PY - 2013/4

Y1 - 2013/4

N2 - Nodal peripheral T-cell lymphoma (nodal PTCL) has an unfavorable prognosis, and specific pathogenic alterations have not been fully identified. The biological and clinical relevance of the expression of CD30/T-cell receptor (TCR) genes is a topic under active investigation. One-hundred and ninety-three consecutive nodal PTCLs (89 angioimmunoblastic T-cell lymphomas (AITL) and 104 PTCL-unspecified (PTCL-not otherwise specified (NOS)) cases) were analyzed for the immunohistochemical expression of 19 molecules, involving TCR/CD30 pathways and the associations with standard prognostic indices. Mutually exclusive expression was found between CD3 and TCR-beta F1 with CD30 expression. Taking all PTCL cases together, logistic regression identified a biological score (BS) including TCR molecules (TCR-beta F1 and EZRIN) that separates two subgroups of patients with a median survival of 34.57 and 5.20 months (P

AB - Nodal peripheral T-cell lymphoma (nodal PTCL) has an unfavorable prognosis, and specific pathogenic alterations have not been fully identified. The biological and clinical relevance of the expression of CD30/T-cell receptor (TCR) genes is a topic under active investigation. One-hundred and ninety-three consecutive nodal PTCLs (89 angioimmunoblastic T-cell lymphomas (AITL) and 104 PTCL-unspecified (PTCL-not otherwise specified (NOS)) cases) were analyzed for the immunohistochemical expression of 19 molecules, involving TCR/CD30 pathways and the associations with standard prognostic indices. Mutually exclusive expression was found between CD3 and TCR-beta F1 with CD30 expression. Taking all PTCL cases together, logistic regression identified a biological score (BS) including TCR molecules (TCR-beta F1 and EZRIN) that separates two subgroups of patients with a median survival of 34.57 and 5.20 months (P

KW - BLIMP1

KW - EZRIN

KW - JUNB

KW - T-cell lymphoma

KW - TCR-beta F1

UR - http://www.scopus.com/inward/record.url?scp=84878322681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878322681&partnerID=8YFLogxK

U2 - 10.1038/bcj.2013.10

DO - 10.1038/bcj.2013.10

M3 - Article

C2 - 23599023

AN - SCOPUS:84878322681

VL - 3

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 4

M1 - e111

ER -

Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this